October 29, 2024
Authored and Edited by A. Sasha Hoyt; Christopher B. Anderson; Sonja W. Sahlsten; Prince M. Ene, Pharm. D.
In Provisur Technologies, Inc. v. Weber, Inc., No. 2023-1438 (Fed. Cir. Oct. 2, 2024), the Federal Circuit issued a mixed ruling, affirming infringement findings for two of three patents and reversing decisions on willfulness and damages.
Provisur accused Weber of infringing claims of three patents related to high-speed mechanical food slicers. A jury found Weber willfully infringed all three patents and awarded over $10 million in damages. Weber moved for judgment as a matter of law and a new trial. The district court denied both motions.
On appeal, the Federal Circuit reversed the jury’s findings of infringement for one of the patents at issue,[1] finding Provisur failed to proffer substantial evidence of infringement. While some evidence suggested it was possible to reconfigure Weber’s accused products in an infringing manner, no evidence of record demonstrated Weber’s products were sold in an infringing configuration or that they could be reprogrammed by its customers to activate such a configuration.
Regarding willfulness, the Federal Circuit found that the district court improperly admitted expert testimony regarding Weber’s purported failure to seek a freedom to operate analysis or other legal services from a third party, in violation of 35 U.S.C. § 298. The remaining evidence, while admissible, failed to establish Weber’s specific intent to infringe as a matter of law.
Finally, the Federal Circuit found that the district court improperly permitted Provisur to use the “entire market value rule” for damages, rather than calculate a reasonable royalty based on apportionment between infringing and non-infringing features of Weber’s products. Weber’s systems included several non-infringing features—some of which Weber itself patented—and Provisur’s expert offered no evidence that Provisur’s patented features alone drove customer demand for Weber’s entire slicing systems or substantially created its value. The case was remanded for a new trial on damages.
[1] Weber conceded infringement of the remaining two patents during oral argument due to an intervening decision.
Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.